Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for Prostate Cancer
June 12th 2019A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for metastatic castration-resistant prostate cancer.
Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL
June 11th 2019Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Dr. Debu Tripathy on Ribociclib Plus Hormone Therapy for Breast Cancer Patients
June 10th 2019Cancer Network spoke with Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, on how ribociclib plus hormone therapy extends survival for patients with premenopausal advanced HR-positive breast cancer.
Dr. Chiara Cremolini on the Updated Results of the TRIBE2 Study for Unresectable Colorectal Cancer
June 10th 2019Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
Investigators Are Assessing an Experimental Interleukin-2 Drug in Patients With Metastatic Melanoma
June 5th 2019A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2–based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients.